

Martin Laimer

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5713229/publications.pdf>

Version: 2024-02-01

42
papers

610
citations

687363

13
h-index

677142

22
g-index

52
all docs

52
docs citations

52
times ranked

730
citing authors

#	ARTICLE	IF	CITATIONS
1	“Pyoderma gangrenosum” a lifelong chronic disease. A 10 Year Clinical follow up of a Pyoderma Patient. Journal of Plastic, Reconstructive and Aesthetic Surgery, 2022, , .	1.0	0
2	Efficacy and safety of nivolumab for locally advanced or metastatic cutaneous cell carcinoma (NIVOSQUACS trial).. Journal of Clinical Oncology, 2022, 40, 9528-9528.	1.6	1
3	Similar clinical outcome of AMA immunoblot-M2-negative compared to immunoblot-positive subjects over six years of follow-up. Postgraduate Medicine, 2021, 133, 291-298.	2.0	5
4	Clinical Perspectives of Gene-Targeted Therapies for Epidermolysis Bullosa. Dermatology and Therapy, 2021, 11, 1175-1197.	3.0	13
5	Adjuvant anti-PD-1 antibody treatment in stage III/IV melanoma: real-world experience and health economic considerations. JDDG - Journal of the German Society of Dermatology, 2021, 19, 1186-1198.	0.8	3
6	The natural history of laryngoonycho-cutaneous syndrome: A case series of six pediatric patients and literature review. Pediatric Dermatology, 2021, 38, 1094-1101.	0.9	4
7	COVID-19-Induced Reduction in Primary Melanoma Diagnoses: Experience from a Dermatopathology Referral Center. Journal of Clinical Medicine, 2021, 10, 4059.	2.4	13
8	History of Repeated Bleeding from Intact Skin and Mucous Membranes: A Quiz. Acta Dermato-Venereologica, 2021, 101, adv00592.	1.3	0
9	Impact of low-dose calcipotriol ointment on wound healing, pruritus and pain in patients with dystrophic epidermolysis bullosa: A randomized, double-blind, placebo-controlled trial. Orphanet Journal of Rare Diseases, 2021, 16, 473.	2.7	7
10	Growth profile and anaemia in children with epidermolysis bullosa. British Journal of Dermatology, 2020, 182, 1327-1328.	1.5	2
11	Translational perspectives to treat Epidermolysis bullosa “Where do we stand?. Experimental Dermatology, 2020, 29, 1112-1122.	2.9	10
12	Profiling trial burden and patients’ attitudes to improve clinical research in epidermolysis bullosa. Orphanet Journal of Rare Diseases, 2020, 15, 182.	2.7	11
13	A novel humanized mouse model to study the function of human cutaneous memory T cells in vivo in human skin. Scientific Reports, 2020, 10, 11164.	3.3	11
14	EB (epidermolysis bullosa) – Austria: Pioneering work for the care of patients with rare diseases. JDDG - Journal of the German Society of Dermatology, 2020, 18, 1229-1235.	0.8	3
15	Dermatologische Fortbildung in Österreich: Neue Programmformate bei der OEADF-Jahrestagung in Graz. JDDG - Journal of the German Society of Dermatology, 2019, 17, 761-762.	0.8	0
16	Epidermolysis bullosa: Advances in research and treatment. Experimental Dermatology, 2019, 28, 1176-1189.	2.9	51
17	Wound healing deficits in severe generalized recessive dystrophic epidermolysis bullosa along anticancer treatment with cetuximab. JDDG - Journal of the German Society of Dermatology, 2019, 17, 448-450.	0.8	12
18	Extended surgical safety margins and ulceration are associated with an improved prognosis in pleomorphic dermal sarcomas. Journal of the European Academy of Dermatology and Venereology, 2019, 33, 1577-1580.	2.4	31

#	ARTICLE	IF	CITATIONS
19	Epidermolysis bullosa House Austria as a role model for the care of a rare disease. <i>Almanah Kliničeskoj Mediciny</i> , 2019, 47, 2-11.	0.3	0
20	Diacerein orphan drug development for epidermolysis bullosa simplex: A phase 2/3 randomized, placebo-controlled, double-blind clinical trial. <i>Journal of the American Academy of Dermatology</i> , 2018, 78, 892-901.e7.	1.2	48
21	Vismodegib for recurrent locally destructive basal cell carcinoma in a renal transplant patient. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018, 32, e7-e8.	2.4	5
22	Low-dose calcipotriol can elicit wound closure, anti-microbial, and anti-neoplastic effects in epidermolysis bullosa keratinocytes. <i>Scientific Reports</i> , 2018, 8, 13430.	3.3	24
23	Confocal Microscopy in Skin Cancer. <i>Current Dermatology Reports</i> , 2018, 7, 105-118.	2.1	41
24	Scalp tumors. <i>JDDG - Journal of the German Society of Dermatology</i> , 2018, 16, 730-753.	0.8	22
25	Epidermolysis bullosa House Austria and Epidermolysis bullosa clinical network. <i>Wiener Klinische Wochenschrift</i> , 2017, 129, 1-7.	1.9	10
26	Noninvasive RCM for Differentiation of Melanotic Macules From Melanocytic Lesions – Blinded Evaluation of a Series of 42 Pigmented Macules. <i>Dermatologic Surgery</i> , 2017, 43, 911-919.	0.8	7
27	MAPK14 as candidate for genetic susceptibility to diabetic foot ulcer. <i>British Journal of Dermatology</i> , 2017, 177, 1482-1483.	1.5	4
28	Papillary intralymphatic angioendothelioma (<sc>PILA</sc>), also referred to as Dabska tumour, in an 83-year-old woman. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2016, 30, e59-e61.	2.4	5
29	Verrucous seborrheic keratosis with keratoacanthoma-like features, a pitfall in differential diagnosis. <i>JDDG - Journal of the German Society of Dermatology</i> , 2015, 13, 911-913.	0.8	8
30	Lymphatic Markers in the Adult Human Choroid. , 2015, 56, 7406.		29
31	Hereditary epidermolysis bullosa. <i>JDDG - Journal of the German Society of Dermatology</i> , 2015, 13, 1125-1133.	0.8	24
32	Hereditäre Epidermolysen. <i>JDDG - Journal of the German Society of Dermatology</i> , 2015, 13, 1125-1134.	0.8	23
33	Generalized Severe Junctional Epidermolysis Bullosa. , 2015, , 375-380.		0
34	Autoimmune Bullous Diseases in Austria. <i>Dermatologic Clinics</i> , 2011, 29, 691-698.	1.7	2
35	Diffuse Cutaneous Mastocytosis Masquerading as Epidermolysis Bullosa. <i>Pediatric Dermatology</i> , 2011, 28, 720-725.	0.9	21
36	Skin clues of systemic diseases. <i>Expert Review of Dermatology</i> , 2011, 6, 559-561.	0.3	0

#	ARTICLE	IF	CITATIONS
37	Herlitz Junctional Epidermolysis Bullosa. <i>Dermatologic Clinics</i> , 2010, 28, 55-60.	1.7	63
38	Epidermolysis Bullosa Nevi. <i>Dermatologic Clinics</i> , 2010, 28, 179-183.	1.7	32
39	Vincristine, Idarubicin, Dexamethasone and Thalidomide in Scleromyxoedema. <i>Acta Dermato-Venereologica</i> , 2009, 89, 631-635.	1.3	12
40	Nonsense-associated altered splicing of the Patched gene fails to suppress carcinogenesis in Gorlin syndrome. <i>British Journal of Dermatology</i> , 2008, 159, 222-227.	1.5	6
41	Current approaches to cutaneous gene therapy. <i>Expert Review of Dermatology</i> , 2006, 1, 833-853.	0.3	1
42	Introducing a fast and simple PCR-RFLP analysis for the detection of mutant thiopurine S-methyltransferase alleles TPMT*3A and TPMT*3C. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2006, 20, 396-400.	2.4	18